New drug tested for Tough-to-Treat skin cancer
NCT ID NCT05944562
Summary
This early-stage study is testing a new drug called tulmimetostat (DZR123) in patients with advanced mycosis fungoides or Sézary syndrome, which are types of skin lymphoma. The main goal is to check if the drug is safe and to find the right dose for future studies. Researchers will also look for early signs that the drug might help control the cancer in patients whose disease has continued despite previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.